News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF Therapy at the 4thQuadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)

Al's Comment:

15  abstracts were presented at this meeting, most from researchers not  connected to the company that makes the device.  That is a great sign that this new treatment modality is becommoing accepted by the mainstream brain tumor community. Although the  system has been approved by the FDA  in2011 to treat recurrent GBMs, and is listed  as the standard of care in the NCCN guidelines for treatment of recurrent  glioblastoma,some  treatment centers have been slow to  use the device.  Now over 110  centers  in  the USA use it!


Posted on: 12/15/2013

Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF Therapy at the 4thQuadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) 

http://virtualtrials.com/pdf/novocuresno.pdf

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740